Presumptive identification of *Clostridium difficile* 027/NAP1/BI on Cepheid Xpert® - interpret with caution

Jen KOK*, Qinning WANG, Lee C THOMAS, Gwendolyn L GILBERT

Centre for Infectious Diseases and Microbiology Laboratory Services, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, New South Wales 2145, Australia

*Correspondence to:
Dr Jen KOK
Centre for Infectious Diseases and Microbiology Laboratory Services
Level 3, Institute of Clinical Pathology and Medical Research
Westmead Hospital, Westmead, New South Wales 2145

AUSTRALIA

Telephone: 61 2 9845 6255
Fax: 61 2 9893 8659
Email: jen.kok@swahs.health.nsw.gov.au

Keywords: *Clostridium difficile*; 027/NAP1/BI; PCR; Strain typing; Infection control

Word Count: 1054
The prevalence of hospital and community-acquired *Clostridium difficile* infection (CDI) has recently increased, particularly in the Northern Hemisphere, with spread of the hypervirulent 027/NAP1/BI strain; so far, this strain is uncommon in Australia.

Rapid, accurate laboratory diagnosis of CDI guides patient management and infection control; rapid identification of 027/NAP1/BI, which can cause fulminant disease, helps predict the clinical course (3,16).

In pathogenic *C. difficile*, toxins A and B are encoded by *tcdA* and *tcdB* respectively and their expression is regulated by *tcdR* (positive regulator) and *tcdC* (negative regulator). It has been hypothesized that hypervirulence in 027/NAP1/BI is due to increased toxin A/B production as a result of a single-base deletion at nucleotide position 117 in *tcdC*; and the production of binary toxin CDT, encoded by *cdtA* and *cdtB* (9). There is also a characteristic 18 bp deletion in *tcdC* (nucleotide position 330 to 347), which alone does not affect function (9).

Molecular typing of *C. difficile* is generally done in reference laboratories, with resulting delays of days to weeks. The Xpert® *C. difficile* Epi assay (Xpert; Cepheid, Sunnyvale, CA) is a real-time, multiplex PCR assay that allows presumptive identification of 027/NAP1/BI by detecting *tcdB*, *cdt* and the single-base deletion in *tcdC* in stool samples or isolates (1), with reported sensitivities and specificities of 96.6%-99.7% and 93.0%-98.6% respectively (1,5,13). Herein, we describe presumptive identification of 027/NAP1/BI by Xpert, in three stool specimens, which contained toxigenic *C. difficile*, but not 027/NAP1/BI.

In our laboratory, liquid stool specimens are tested by C. DIFF QUIK CHEK COMPLETE® (TechLab, Blacksburg, VA) enzyme immunoassay for glutamate
dehydrogenase (GDH) and toxins A/B. GDH positive, toxin A/B negative and GDH negative, toxin A/B positive specimens are tested with Xpert to confirm the presence of toxigenic *C. difficile* DNA and for preliminary identification of 027/NAP1/BI. GDH, toxin A/B positive; and Xpert-positive stool specimens are cultured on cycloserine cefoxitin fructose agar (CCFA) for 48h at 37°C, and confirmed as *C. difficile* using the RapID™ ANA II System (Remel Inc., Lenexa, KS). Moxifloxacin susceptibility testing, by disk diffusion and E-test (AB Biodisk, Solna, Sweden), are interpreted according to CLSI breakpoints (2). Isolates are subjected to PCR-ribotyping, using a modified method incorporating capillary gel electrophoresis (12).

*C. difficile* 027/NAP1/BI is still rare in Australia, with only two cases and a single outbreak involving five patients reported prior to 2011 (10,11,15). However, a more recent investigation found that 5.3% of all *C. difficile* isolates typed from one Area Health Service in New South Wales, between March 2009 and November 2010, were 027/NAP1/BI (6), although none had been identified elsewhere in the State. Therefore, notwithstanding the effect of low prevalence on positive predictive values (and false positive rates) (7), we were surprised by the presumptive identification of 027/NAP1/BI by Xpert, in three of 101 stool specimens (of which 71 were subsequently shown to contain toxigenic *C. difficile*), within a 16 week period. Prior to this, Xpert had not identified any presumptive 027/NAP1/BI in clinical specimens referred from within our Area Health Service or other laboratories.

Xpert testing of cultured isolates from all three specimens was positive for *tcdB* but not for either *cdt* or the *tcdC* deletion. PCR-ribotyping identified one as similar to ribotype 078, but the others did not match any reference strains in our database. PCR-ribotype 078, in common with 027/NAP1/BI, contains *tcdA*, *tcdB*, and
binary toxin but, unlike the latter, has a 39 bp deletion and a point mutation at position 68 in tcdC (4). Moxifloxacin resistance, which is characteristic of, but not specific for, 027/NAP1/BI, was only present in the isolate resembling ribotype 078.

Sequencing of tcdC in all three isolates showed the typical 18 bp deletion at nucelotide position 330 to 347 (8) and an extra 21 bp deletion at position 354 to 374 in two, including the isolate initially identified as ribotype 078. The latter did not contain the 39 bp deletion or point mutation at position 184, suggesting that it was not a typical 078 strain. Interestingly, all three isolates showed an A>T mutation at position 117 of tcdC, different from the characteristic single-base deletion in 027/NAP1/BI. These three tcdC sequences were subsequently assigned GenBank accession numbers JF719678, JF719679, and JF719680.

Xpert amplification curves of the three stool specimens differed from that of the positive 027/NAP1/BI control strain (a clinical isolate previously provided by another laboratory that was confirmed as 027/NAP1/BI by PCR-ribotyping and tcdC sequencing) (Figure 1), in that only the cdt curve was prominent whereas both cdt and tcdC gene deletion targets were pronounced in the control. Although the Xpert identified a single-base deletion at position 117 of tcdC, the amplification curve generated was flat compared to that of the control, possibly related to the A>T mutation at the same position. The significance of this mutation is unknown, but may explain the false positive Xpert result. Melt curve analysis, which is not available with Xpert at present, would have allowed further differentiation of 027/NAP1/BI and non-027/NAP1/BI strains.

Although Xpert can provide rapid laboratory diagnosis of C. difficile and presumptive 027/NAP1/BI identification in stool within 45 minutes (8), it is
suggested that positive results be confirmed by formal typing of cultures, particularly in areas of low prevalence. However, typing of \textit{C. difficile} isolates may not be available in all laboratories. Although multiple strains of \textit{C. difficile} may coexist in faecal samples (14), it is unlikely that this explains our false positive Xpert results. We prepared DNA from a sweep of each CCFA plate where \textit{C. difficile} was cultured for PCR-ribotyping, which should have included mixed strains if present. A North American study recently reported five stool samples in which 027/NAP1/BI were identified by Xpert, but not confirmed by two or more typing methods (PCR-ribotyping, PFGE and/or REA) (13); the five isolates could not be characterized by these typing methods.

To our knowledge, this is the first report of unusual Xpert amplification curves from stool samples presumptively identified as 027/NAP1/BI, but not confirmed by PCR-ribotyping and \textit{tcdC} gene sequencing. It is unlikely that PFGE or REA would have provided useful additional information, given the high Wallace coefficients between them and PCR-ribotyping (13). Unlike the North American experience (13), we were able to characterize one of the three isolates using PCR-ribotyping. We caution users of Xpert to closely examine amplification curves of presumptive 027/NAP1/BI for unusual patterns, to avoid misidentification of 027/NAP1/BI.
Acknowledgements and conflicts of interest (all authors)

Conflict of interest: Nothing to declare

Funding: No funding or other financial support was received in the preparation of this manuscript
References


Figure 1. Amplification curves generated by Xpert depicting fluorescence of toxin B (green), binary toxin (cdt; turquoise), single nucleotide deletion at position 117 in tcdC (purple) and positive control (blue) vs. cycle number for “presumptive 027/NAP1/BI”. Top graph depicts a representative pattern of three non-027/NAP1/BI stool specimens (curves for the other two isolates were similar); bottom graph, positive 027/NAP1/BI control.